PYPD Polypid

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European Society for Coloproctology Scientific Conference

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European Society for Coloproctology Scientific Conference

Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection will be Presented During a Podium Presentation

PETACH TIKVA, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data for D-PLEX100 will be highlighted in a podium presentation at the European Society for Coloproctology (ESCP) Scientific Conference to be held on September 21-23, 2022, in Dublin, Ireland.

European Society for Coloproctology Scientific Conference:

Title: D-PLEX100, a novel doxycycline formulation that provides high, local concentrations of antibiotic activity for 30 days to reduce surgical site infections
Presenter:Anthony J. Senagore, M.D., Senior Medical Director, PolyPid
Date:Wednesday, September 21, 2022, part of the Modern Colorectal Surgeon session

The abstract will be available on  /publications/ following the presentation.

About PolyPid

(Nasdaq: ) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit and follow us on and .

Contacts: 

PolyPid Ltd. 

Ori Warshavsky

COO – US

908-858-5995

Investors:

Bob Yedid

LifeSci Advisors

646-597-6989

 



EN
12/09/2022

Underlying

PYPDPolypid

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Polypid

 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of th...

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application Submission PETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. “Brooke’s appointment marks an exciting and pivotal moment for PolyPid,” sai...

December 16, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ S...

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission NDA to be Submitted on a Rolling Basis, Beginning Early 2026 PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New Drug Application (“NDA”) meeting minutes from the U.S. Food and Drug Administration (“FDA”) supporting the NDA submission of D-PLEX100, the Company’s lead product candidate for the prevention of surgic...

December 3, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on D...

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025 Internationally recognized colorectal surgeon Steven D. Wexner, MD, FACS, FRCS, to discuss the clinical and economic burden of surgical site infections and the therapeutic potential of D-PLEX₁₀₀ PETACH TIKVA, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will participate in a virtual Key Opinion Leader (KOL) event hosted by ROTH Capital Partners. KOL Event ...

November 25, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Finan...

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial Results Company Continues to Advance Towards Commercial Manufacturing Readiness with Successful Completion of IMOH GMP Inspection Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"),...

November 12, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics ...

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year" PolyPid's Lead Candidate Recognized for Addressing Critical Unmet Need in Surgical Site Infection Prevention Following Positive Phase 3 Results PETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company focused on improving surgical outcomes, today announced that D-PLEX₁₀₀, the company’s lead candidate, has been named "Therapeutics Solution of the Year" by , a leading independent market intelligence organization which evalu...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch